Evercore ISI analyst Umer Raffat maintained a Buy rating on Biogen (BIIB – Research Report) yesterday. The company’s shares closed yesterday at ...

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs. Despite this ...